MBRX Reports 40% Preliminary CRc Rate, 67% Blinded CR Improvement, 35% Veneto Failures, 45-Subject Q1 2026 Unblinding Milestone
Moleculin Biotech, Inc. · PHARMACEUTICAL PREPARATIONS · Now $2.64
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS